Yipinhong announced on August 21. Recently, the drug clinical trial application for the innovative drug APH03867 tablets independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been approved by the State Drug Administration, and a “Drug Clinical Trial Approval Notice” has been received, and clinical trials will be carried out in the near future. This product is intended for the treatment of patients with gout with hyperuricemia.

Yipinhong announced on August 21. Recently, the drug clinical trial application for the innovative drug APH03867 tablets independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has been approved by the State Drug Administration, and a “Drug Clinical Trial Approval Notice” has been received, and clinical trials will be carried out in the near future. This product is intended for the treatment of patients with gout with hyperuricemia.